GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: RP-54476 | RP54476 | Synercid® (dalfopristin + quinupristin)
                                 dalfopristin is an approved drug (FDA (1999)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Dalfopristin is a semi-synthetic derivative of pristinamycin IIA (streptogramin A). It inhibits the early phase of protein synthesis in the bacterial ribosome by binding to the 70S subunit. It is administered intravenously.
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| No information available. | 
| Summary of Clinical Use  | 
| Dalfopristin is intravenously administered in fixed combination with quinupristin to treat severe bacterial infections due to susceptible organisms including methicillin resistant Staphylococcus aureus (MRSA) or Streptococcus pyogenes. | 
| External links  | 
| For extended ADME data see the following: Drugs.com |